| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.1 | 0.6 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |